Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. Class A Common Stock (LIMN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
limn · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Liminatus Pharma, Inc. Class A Common Stock (LIMN) measures how much investors pay for each dollar of the company's trailing earnings. LIMN's current PE ratio of N/A is calculated by dividing its stock price of $0.14 by its TTM earnings per share of -$0.46.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2021 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Liminatus Pharma, Inc. Class A Common StockYou LIMN | $4M | N/A | — | -$0.46 |
 Alterity Therapeutics Limited ATHE | $36M | N/A | — | -$1.14 |
 BioXcel Therapeutics, Inc. BTAI | $34M | N/A | — | -$5.73 |
 Dyadic International, Inc. DYAI | $25M | N/A | — | -$0.23 |
 Evaxion Biotech A/S EVAX | $24M | N/A | — | -$1.20 |
 Generation Bio Co. GBIO | $36M | N/A | — | -$19.76 |
 Jasper Therapeutics, Inc. JSPR | $8M | N/A | — | -$3.95 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.43 | — | |
2024-12-31 FY2024 | — | $-0.40 | — | |
2023-12-31 FY2023 | — | $-0.15 | — | |
2022-12-31 FY2022 | — | $-0.09 | — | |
2021-12-31 FY2021 | 39.56x | $0.13 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Liminatus Pharma, Inc. Class A Common Stock (LIMN) measures how much investors pay for each dollar of the company's trailing earnings. LIMN's current PE ratio of N/A is calculated by dividing its stock price of $0.14 by its TTM earnings per share of -$0.46.
Frequently asked questions
LIMN pe ratio · 6 questionsLIMN's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.14 and TTM EPS of -$0.46. Data sourced from Financial Modeling Prep via LIMN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Liminatus Pharma, Inc. Class A Common Stock SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09